Vor to Participate in Piper Sandler 33rd Virtual Annual Healthcare ConferenceGlobeNewsWire • 11/19/21
Does Vor Biopharma (VOR) Have the Potential to Rally 186% as Wall Street Analysts Expect?Zacks Investment Research • 11/15/21
Vor to Present New Data on its Cell and Genome Engineering Platform at SITC Annual MeetingGlobeNewsWire • 11/09/21
Vor to Present Data from its Novel Cell and Genome Engineering Platform at ESGCTGlobeNewsWire • 10/19/21
Vor Strengthens Leadership Team with Addition of Dr. Veit Schmelmer as SVP of Program and Alliance ManagementGlobeNewsWire • 10/12/21
PureTech Founded Entity Vor Biopharma Announces VOR33 Granted U.S. FDA Fast Track Designation for Acute Myeloid LeukemiaBusiness Wire • 09/10/21
Vor Reports Second Quarter 2021 Financial Results and Provides Company UpdateGlobeNewsWire • 08/09/21
PureTech Founded Entity Vor Biopharma Announces Collaboration with Janssen to Develop Engineered Hematopoietic Stem Cell Transplants Combined with a Bi-Specific Antibody Therapy for Acute Myeloid Leukemia (AML)Business Wire • 07/09/21
Vor Biopharma, Janssen Team Up To Develop Combination Therapies For Acute Myeloid LeukemiaBenzinga • 07/08/21
Vor Biopharma Announces Collaboration with Janssen to Develop Engineered Hematopoietic Stem Cell Transplants Combined With a Bi-Specific Antibody Therapy for Acute Myeloid Leukemia (AML)GlobeNewsWire • 07/08/21
Vor Biopharma Names Matthew R. Patterson as Chairman and Promotes Tania PhilippGlobeNewsWire • 06/11/21
Vor Biopharma Announces Participation at Cowen 41st Annual Health Care ConferenceGlobeNewsWire • 03/01/21
Vor Biopharma Closes Over $200M Initial Public Offering, Including Full Exercise of Option to Purchase Additional SharesGlobeNewsWire • 02/09/21
